Shannon Connelly | Authors


Bekaii-Saab Considers TKI Therapy to Treat Patients With Advanced GI Cancers

June 13, 2019

During a recent Targeted Oncology live case-based peer perspectives presentation, Tanios Bekaii-Saab, MD, discussed with a group of physicians the treatment options for patients with gastrointestinal cancers and the characteristics that influence his decision making. Bekaii-Saab explained his clinical decisions based on the case scenario of one patient with colorectal cancer and one with hepatocellular carcinoma.

Anti-PD-L1 Therapy May Have Benefit in Aggressive Papillary Thyroid Cancer

May 29, 2019

Patients with aggressive papillary thyroid cancer may be good candidates for treatment with anti–PD-(L)1 immunotherapy due to elevated levels of serum PD-L1, according to findings from a new study presented during the 2019 AACR-AHNS Head and Neck Cancer Conference.

FDA Lifts Partial Hold on AIM2CERV Trial of Investigational Immunotherapy Agent in Cervical Cancer

May 15, 2019

The FDA has lifted the partial clinical hold placed on the phase III AIM2CERV trial, which is evaluating axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer, according to Advaxis, the developer of the investigational immunotherapy agent.

Study Findings Support Pelvic Radiation Therapy Over Vaginal Cuff Brachytherapy in Endometrial Cancer

May 08, 2019

Treatment with vaginal cuff brachytherapy plus paclitaxel and carboplatin chemotherapy was not found to be superior to pelvic radiation therapy in patients with high-intermediate and high-risk early-stage endometrial cancer, according to findings from a phase III trial recently published in the Journal of Clinical Oncology.